A carregar...
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect
IMPORTANCE: In 2010, the US Food and Drug Administration (FDA) approved a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect after studies in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). This medication, howeve...
Na minha lista:
| Publicado no: | JAMA Intern Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439654/ https://ncbi.nlm.nih.gov/pubmed/30615021 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2018.6112 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|